RxDoctor Payments Data

Terence Barlow, APRN

Family · Thurmont, MDNPI 1770016321

Payments from drug & device makers

$2,018in general payments, 2019–2025

Across 99 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$280
  • AstraZeneca$207
  • AbbVie$201
  • Exact Sciences$176
  • Amgen$161
  • Boehringer Ingelheim$141
  • plus $851 from 14 others

What the payments were for

  • Food & beverage$1,99999%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,018 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$46,939
Medicare patients
149
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$92,726
FarxigaDapagliflozin Propanediol46$51,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$38,955
JardianceEmpagliflozin35$36,320
TruvadaEmtricitabine/Tenofovir (Tdf)12$21,809
VraylarCariprazine Hcl14$21,431
EliquisApixaban17$15,365
XareltoRivaroxaban20$14,622
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,906
Arnuity ElliptaFluticasone Furoate13$2,892
Bupropion XlBupropion Hcl58$2,845
Albuterol Sulfate HfaAlbuterol Sulfate81$2,566
Gabapentin79$2,185
Duloxetine Hcl41$2,125
SynthroidLevothyroxine Sodium19$1,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$280$92,72677 claims
AstraZenecaFarxiga$207$51,19846 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$136$47,75377 claims
Boehringer IngelheimJardiance$141$36,32035 claims
AbbVieVraylar, Synthroid$201$23,22233 claims
PfizerEliquis$54$15,36517 claims
Lilly USA, LLCOlanzapine$97$55513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Thurmont

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →